Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Surrozen, Inc./DE (SRZN)

Surrozen closes $95.1 million second tranche of March 2025 private placement

Mixed Impact 3 of 5 financing Written later

Surrozen completed the second and final tranche of its March 2025 private placement on October 20, 2026, raising approximately $95.1 million in gross proceeds before placement agent fees and other expenses. The company says the proceeds extend its expected cash runway into 2029, but the issuance adds shares, pre-funded warrants and warrants that dilute existing shareholders.

Key points

  • Issued 5,741,605 common shares at $11.60 per share, plus pre-funded warrants for 2,456,500 shares and Series E warrants for 4,099,052 shares with an exercise price of $11.54
  • Closing was triggered by FDA clearance of the Investigational New Drug application for SZN-8141 announced October 2, 2026
  • Company expects cash runway into 2029, including funding for the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143
  • Company agreed to file a resale registration statement within 30 calendar days of the closing

The filing

CompanySurrozen, Inc./DE (SRZN)
Form8-K, current report
Filed with the SECOct 20, 2026, 5:04 PM ET
Accession number0001193125-26-426828

Items reported: 2.02 Results of Operations3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.